JP2005521393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005521393A5 JP2005521393A5 JP2003577602A JP2003577602A JP2005521393A5 JP 2005521393 A5 JP2005521393 A5 JP 2005521393A5 JP 2003577602 A JP2003577602 A JP 2003577602A JP 2003577602 A JP2003577602 A JP 2003577602A JP 2005521393 A5 JP2005521393 A5 JP 2005521393A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- sirna
- transcript
- infectious agent
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 89
- 108020004459 Small interfering RNA Proteins 0.000 claims 53
- 210000004027 cell Anatomy 0.000 claims 48
- 239000012678 infectious agent Substances 0.000 claims 38
- 208000015181 infectious disease Diseases 0.000 claims 27
- 241000700605 Viruses Species 0.000 claims 21
- 239000013598 vector Substances 0.000 claims 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 230000010076 replication Effects 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 6
- 230000001105 regulatory effect Effects 0.000 claims 5
- 230000015556 catabolic process Effects 0.000 claims 4
- 238000006731 degradation reaction Methods 0.000 claims 4
- 230000001934 delay Effects 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000002458 infectious effect Effects 0.000 claims 3
- 230000010468 interferon response Effects 0.000 claims 3
- 230000009467 reduction Effects 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 claims 1
- 108020004394 Complementary RNA Proteins 0.000 claims 1
- 102000014450 RNA Polymerase III Human genes 0.000 claims 1
- 108010078067 RNA Polymerase III Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 230000014616 translation Effects 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36592502P | 2002-03-20 | 2002-03-20 | |
| US39604102P | 2002-07-15 | 2002-07-15 | |
| PCT/US2003/008653 WO2003079757A2 (en) | 2002-03-20 | 2003-03-20 | Hiv therapeutic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005521393A JP2005521393A (ja) | 2005-07-21 |
| JP2005521393A5 true JP2005521393A5 (enExample) | 2006-05-11 |
Family
ID=28457122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003577602A Pending JP2005521393A (ja) | 2002-03-20 | 2003-03-20 | Ｈｉｖ治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040248296A1 (enExample) |
| EP (1) | EP1495141A4 (enExample) |
| JP (1) | JP2005521393A (enExample) |
| AU (1) | AU2003224725A1 (enExample) |
| CA (1) | CA2479530A1 (enExample) |
| WO (1) | WO2003079757A2 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1257289A1 (en) | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| AU2003261449A1 (en) | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
| EP2000160A3 (en) * | 2002-10-30 | 2009-03-11 | Gambro Lundia AB | Method and apparatuses for determining the efficiency of dialysis |
| US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
| US7592442B2 (en) * | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
| US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US20100113307A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
| US7691998B2 (en) * | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
| US7619081B2 (en) * | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
| US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US7977471B2 (en) * | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
| US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7612196B2 (en) * | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
| US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
| US20090227780A1 (en) * | 2002-11-14 | 2009-09-10 | Dharmacon, Inc. | siRNA targeting connexin 43 |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
| US20080268457A1 (en) * | 2002-11-14 | 2008-10-30 | Dharmacon, Inc. | siRNA targeting forkhead box P3 (FOXP3) |
| US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
| US7635770B2 (en) * | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
| US20040191905A1 (en) * | 2002-11-22 | 2004-09-30 | University Of Massachusetts | Modulation of HIV replication by RNA interference |
| CA2513679A1 (en) | 2003-01-17 | 2004-08-05 | University Of Florida | Small interference rna gene therapy |
| JP2006526394A (ja) * | 2003-06-03 | 2006-11-24 | ベニテック オーストラリア リミテッド | 二本鎖核酸 |
| WO2005012483A2 (en) * | 2003-08-01 | 2005-02-10 | International Therapeutics, Inc. | Vpr selective rnai agents and methods for using the same |
| ATE494011T1 (de) | 2003-09-17 | 2011-01-15 | Rodos Biotarget Gmbh | Lipid-arzneimittel-formulierungen zur gezielten pharmakotherapie von myeloiden und lymphoiden immunzellen |
| US7612195B2 (en) * | 2003-10-22 | 2009-11-03 | Aventis Pharmaceuticals Inc. | Retroviral vectors for delivery of interfering RNA |
| CA2558771C (en) | 2004-03-05 | 2013-01-08 | Benitec, Inc. | Multiple promoter expression cassettes for simultaneous delivery of rnai agents |
| JP5243789B2 (ja) | 2004-03-15 | 2013-07-24 | シティ・オブ・ホープ | 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物 |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US7605250B2 (en) * | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
| EP1627563A1 (en) | 2004-08-10 | 2006-02-22 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Means and methods for producing a stabilized cell of interest |
| EP1789447B1 (en) | 2004-08-16 | 2012-04-25 | Immune Disease Institute, Inc. | Method of delivering rna interference and uses thereof |
| CA2581651C (en) * | 2004-10-01 | 2014-12-16 | Novartis Vaccines And Diagnostics, Inc. | Cholesterol-labelled modified rna |
| US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
| JP4131271B2 (ja) * | 2005-03-30 | 2008-08-13 | ソニー株式会社 | 情報処理装置および方法、並びにプログラム |
| USRE49583E1 (en) | 2005-11-17 | 2023-07-18 | Tet Systems Gmbh & Co. Kg | Inducible expression systems |
| ES2366227T3 (es) | 2005-11-17 | 2011-10-18 | TET Systems GmbH & Co. KG | Sistemas de expresión inducibles. |
| WO2007067032A1 (en) | 2005-12-09 | 2007-06-14 | Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| US9127251B2 (en) | 2005-12-09 | 2015-09-08 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of antibody producing cells |
| US20100129437A1 (en) | 2007-03-23 | 2010-05-27 | Bbb Holding B.V. | Targeted intracellular delivery of antiviral agents |
| EP2231176A2 (en) * | 2007-12-14 | 2010-09-29 | The Brigham and Women's Hospital, Inc. | Treatment and prevention of hiv infection |
| WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| US8728458B2 (en) | 2009-04-30 | 2014-05-20 | The Regents Of The University Of California | Combination anti-HIV vectors, targeting vectors, and methods of use |
| EP2454283B1 (en) | 2009-07-15 | 2018-03-14 | AIMM Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| US9799416B2 (en) * | 2009-11-06 | 2017-10-24 | Terrapower, Llc | Methods and systems for migrating fuel assemblies in a nuclear fission reactor |
| CU23896B1 (es) * | 2010-04-01 | 2013-05-31 | Ct De Ingeniería Genética Y Biotecnología | Método para inhibir la replicación del vih en células de mamíferos |
| US8785121B2 (en) | 2010-07-08 | 2014-07-22 | Bonac Corporation | Single-stranded nucleic acid molecule for controlling gene expression |
| US8691782B2 (en) | 2010-08-03 | 2014-04-08 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
| WO2012075337A2 (en) | 2010-12-01 | 2012-06-07 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
| ES2626671T3 (es) | 2010-12-02 | 2017-07-25 | Aimm Therapeutics B.V. | Medios y métodos para producir anticuerpos de alta afinidad |
| WO2013077446A1 (ja) * | 2011-11-26 | 2013-05-30 | 株式会社ボナック | 遺伝子発現制御のための一本鎖核酸分子 |
| US9663784B2 (en) | 2012-05-26 | 2017-05-30 | Bonac Corporation | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function |
| CN105899663B (zh) | 2013-12-26 | 2019-07-26 | 学校法人东京医科大学 | 用于基因表达控制的人工模拟miRNA及其用途 |
| CN106068324B (zh) | 2013-12-27 | 2020-12-29 | 株式会社博纳克 | 控制基因表达的人工匹配型miRNA及其用途 |
| DK3099709T3 (da) | 2014-01-31 | 2020-02-03 | Aimm Therapeutics Bv | Midler og fremgangsmåder til fremstilling af stabile antistoffer |
| BR112017013664A2 (pt) | 2014-12-27 | 2018-03-13 | Bonac Corporation | mirna de tipo natural, composição, métodos para inibir expressão de um gene alvo e para tratar uma doença, e, ácido nucleico de fita simples. |
| HK1244031A1 (en) | 2015-03-27 | 2018-07-27 | Bonac Corporation | Single-chain nucleic acid molecule having delivery function and gene expression control ability |
| US11980663B2 (en) | 2015-07-08 | 2024-05-14 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| IL279520B2 (en) | 2016-01-15 | 2023-03-01 | American Gene Tech Int Inc | Methods and preparations for the activation of gamma-delta t cells |
| WO2017139065A1 (en) | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Hiv vaccination and immunotherapy |
| EP3426777B1 (en) | 2016-03-09 | 2022-02-16 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| WO2017213697A1 (en) | 2016-06-08 | 2017-12-14 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
| EP3481418A4 (en) | 2016-07-08 | 2020-03-11 | American Gene Technologies International Inc. | PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV |
| EP3487507A4 (en) | 2016-07-21 | 2020-04-08 | American Gene Technologies International, Inc. | VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE |
| EP3607072A4 (en) | 2017-04-03 | 2021-01-06 | American Gene Technologies International Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF PHENYLCETONURISM |
| US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866701A (en) * | 1988-09-20 | 1999-02-02 | The Board Of Regents For Northern Illinois University Of Dekalb | HIV targeted hairpin ribozymes |
| US5693535A (en) * | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
| US5714320A (en) * | 1993-04-15 | 1998-02-03 | University Of Rochester | Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides |
| NZ267797A (en) * | 1993-05-17 | 1997-09-22 | Univ California | Retroviral vector comprising a ribozyme capable of cleaving a hiv nucleic acid capable |
| US5712384A (en) * | 1994-01-05 | 1998-01-27 | Gene Shears Pty Ltd. | Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
| US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| CA2361201A1 (en) * | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| EP1309726B2 (en) * | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| US20040259247A1 (en) * | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20030175950A1 (en) * | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| US7732193B2 (en) * | 2001-09-13 | 2010-06-08 | California Institute Of Technology | Method for expression of small RNA molecules within a cell |
| US20030203868A1 (en) * | 2002-02-06 | 2003-10-30 | Bushman Frederic D. | Inhibition of pathogen replication by RNA interference |
-
2003
- 2003-03-20 WO PCT/US2003/008653 patent/WO2003079757A2/en not_active Ceased
- 2003-03-20 EP EP03721410A patent/EP1495141A4/en not_active Withdrawn
- 2003-03-20 US US10/393,411 patent/US20040248296A1/en not_active Abandoned
- 2003-03-20 AU AU2003224725A patent/AU2003224725A1/en not_active Abandoned
- 2003-03-20 JP JP2003577602A patent/JP2005521393A/ja active Pending
- 2003-03-20 CA CA002479530A patent/CA2479530A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005521393A5 (enExample) | ||
| US8846632B2 (en) | Nucleic acids for targeting multiple regions of the HCV genome | |
| JP4718379B2 (ja) | 修飾された低分子干渉ｒｎａ分子および使用方法 | |
| CA2853613C (en) | Hbv treatment | |
| US20110117608A1 (en) | Double-stranded nucleic acid | |
| Ruiz et al. | MicroRNA-detargeted mengovirus for oncolytic virotherapy | |
| Kim et al. | Multiple shRNAs driven by U6 and CMV promoter enhances efficiency of antiviral effects against foot-and-mouth disease virus | |
| US8871919B2 (en) | RNAi therapeutic for treatment of Hepatitis C infection | |
| Hong et al. | RNA interference targeting WSSV ribonucleotide reductase 2 provides long-term protection against infection in Litopenaeus vannamei | |
| WO2009002918A2 (en) | Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use | |
| US9574195B2 (en) | RNAi agent for inhibition of Chikungunya virus | |
| KR101077188B1 (ko) | 구제역 바이러스 억제를 위한 ｓｉＲＮＡ를 발현하는 재조합 아데노바이러스 | |
| AU2004243347B2 (en) | Double-stranded nucleic acid | |
| US20100286238A1 (en) | Suppression of viruses involved in respiratory infection or disease | |
| Ely et al. | 799. Expressed Long Hairpin RNA Sequences Inhibit HBV Replication In Vivo without Inducing an Interferon Response | |
| WO2012109798A1 (en) | Hbv treatment | |
| JPWO2021020412A5 (enExample) | ||
| JP2013223426A (ja) | Ｒｒｍ２のアンタゴニストを有効成分として含有するｃ型肝炎治療剤 |